Glucose Intolerance disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: GLC003 MIFTS: 53	Glucose Intolerance Categories: Genetic diseases, Metabolic diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Glucose Intolerance

MalaCards integrated aliases for Glucose Intolerance:

Name: Glucose Intolerance ¹¹ ²⁸ ⁵³ ⁵ ⁴³ ¹⁴ ⁷⁵

Impaired Glucose Tolerance ⁷¹

Malabsorption of Glucose ¹¹

Glucose: Malabsorption ¹¹

Glucose: Intolerance ¹¹

Classifications:

MalaCards categories:
Global: Metabolic diseases Genetic diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:10603

MeSH ⁴³ D018149

NCIt ⁴⁹ C34646

SNOMED-CT ⁶⁸ 267426009

UMLS ⁷¹ C0271650

Sources

Summaries for Glucose Intolerance

MalaCards based summary: Glucose Intolerance, also known as impaired glucose tolerance, is related to lipodystrophy, familial partial, type 2 and abdominal obesity-metabolic syndrome 1. An important gene associated with Glucose Intolerance is MT-TL1 (Mitochondrially Encoded TRNA-Leu (UUA/G) 1), and among its related pathways/superpathways are Signal Transduction and PI3K-Akt signaling pathway. The drugs Curcumin and Orlistat have been mentioned in the context of this disorder. Affiliated tissues include pancreatic islet, skeletal muscle and ovary, and related phenotypes are homeostasis/metabolism and adipose tissue

Wikipedia: ⁷⁵ Prediabetes is a component of the metabolic syndrome and is characterized by elevated blood sugar levels... more...

Sources

Related Diseases for Glucose Intolerance

Diseases related to Glucose Intolerance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 458)

#	Related Disease	Score	Top Affiliating Genes
1	lipodystrophy, familial partial, type 2	32.5	LEP INS ADIPOQ
2	abdominal obesity-metabolic syndrome 1	31.9	SLC2A4 RETN LPL LEPR LEP INS
3	prediabetes syndrome	31.5	SLC2A4 SHBG RETN LPL LEPR LEP
4	non-alcoholic fatty liver disease	31.3	RETN LPL LEPR LEP INSR INS
5	gestational diabetes	31.3	SLC2A4 SHBG RETN LEPR LEP INSR
6	type 1 diabetes mellitus	31.3	LPL LEPR LEP INS IGF1 GHRL
7	coronary heart disease 1	31.2	LPL INS ADIPOQ
8	hypercholesterolemia, familial, 1	31.2	LPL INS GPT
9	polycystic ovary syndrome	31.2	SLC2A4 SHBG RETN LEP INSR INS
10	liver disease	31.1	RETN LEPR LEP INSR INS GPT
11	hyperinsulinism	31.1	SLC2A4 SHBG RETN LPL LEPR LEP
12	non-alcoholic steatohepatitis	31.1	LEP INS GPT GCG ADIPOQ
13	pre-eclampsia	31.1	SHBG LEPR LEP INS IGF1 GPT
14	nutritional deficiency disease	31.1	RETN LEPR LEP IGF1 GHRL ADIPOQ
15	uremia	31.0	RETN LPL LEP INS ENPP1
16	atherosclerosis susceptibility	31.0	RETN LPL LEP INS ADIPOQ
17	familial hyperlipidemia	31.0	LPL LEP INS GCK ADIPOQ
18	acromegaly	31.0	SHBG LEP INS IGF1 GHRL ADIPOQ
19	adult syndrome	31.0	SLC2A4 LEP INS IGF1 ADIPOQ
20	hyperglycemia	31.0	RETN PCK2 LPL LEP INSR INS
21	leptin deficiency or dysfunction	31.0	SLC2A4 RETN LPL LEPR LEP INS
22	chronic kidney disease	31.0	LPL LEP INS IGF1 GHRL ENPP1
23	kidney disease	30.9	RETN LEP INSR INS IGF1 GHRL
24	fatty liver disease	30.9	RETN LPL LEPR LEP INSR INS
25	body mass index quantitative trait locus 11	30.9	SLC2A4 SHBG RETN LPL LEPR LEP
26	liver cirrhosis	30.9	SLC2A4 RETN LEPR LEP INSR INS
27	hyperandrogenism	30.8	SHBG RETN INSR INS IGF1 ADIPOQ
28	hyperthyroidism	30.8	SHBG RETN LEP INS IGF1 GPT
29	cardiovascular system disease	30.8	SHBG RETN LPL LEPR LEP INS
30	insulin-like growth factor i	30.8	SHBG LEP INSR INS IGF1 GHRL
31	type 2 diabetes mellitus	30.8	SLC2A4 SHBG RETN PCK2 LPL LEPR
32	vascular disease	30.8	RETN LPL LEP INS IGF1 ADIPOQ
33	fetal macrosomia	30.7	LEP INSR INS IGF1
34	lipid metabolism disorder	30.7	SLC2A4 SHBG RETN LPL LEPR LEP
35	apnea, obstructive sleep	30.7	RETN LEP INS IGF1 GPT GHRL
36	conn's syndrome	30.7	RETN LEP INS IGF1 GHRL GCG
37	hypothyroidism	30.7	SHBG RETN LPL LEP INS IGF1
38	hypoglycemia	30.7	SLC2A4 PCK2 LEP INSR INS IGF1
39	lipoprotein quantitative trait locus	30.7	RETN LPL INS GPT GCG ADIPOQ
40	pituitary gland disease	30.7	INS IGF1 GCG
41	sleep apnea	30.7	RETN LEPR LEP INS IGF1 GPT
42	arteriosclerosis	30.6	SHBG INS GPT GHRL ADIPOQ
43	heart disease	30.6	RETN LPL INS IGF1 GPT GCG
44	pheochromocytoma	30.6	LEP INSR IGF1 ADRB3 ADIPOQ
45	acanthosis nigricans	30.6	SLC2A4 SHBG LEP INSR INS IGF1
46	acute pancreatitis	30.6	RETN LPL INS GPT
47	anovulation	30.5	SHBG LEP INS IGF1 GHRL
48	peripheral nervous system disease	30.5	LEP INS IGF1 GPT GCG DPP4
49	deficiency anemia	30.5	LEP INS IGF1 GPT GHRL
50	beta-thalassemia	30.5	LEP INS IGF1 GPT

Graphical network of the top 20 diseases related to Glucose Intolerance:

Sources

Symptoms & Phenotypes for Glucose Intolerance

MGI Mouse Phenotypes related to Glucose Intolerance:

⁴⁵ (show all 12)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.36	ADIPOQ ADRB3 DPP4 ENPP1 GCG GCK
2	adipose tissue	MP:0005375	10.27	ADIPOQ ADRB3 ENPP1 GHRL IDE IGF1
3	growth/size/body region	MP:0005378	10.25	ADIPOQ ADRB3 DPP4 ENPP1 GCG GCK
4	muscle	MP:0005369	10.19	ADIPOQ ENPP1 IGF1 INS INSR LEP
5	liver/biliary system	MP:0005370	10.18	ADIPOQ ENPP1 GCK INS INSR LEP
6	endocrine/exocrine gland	MP:0005379	10.18	ADIPOQ ADRB3 DPP4 GCG GCK GHRL
7	renal/urinary system	MP:0005367	10.16	ADIPOQ ENPP1 GCG GCK IGF1 INS
8	cellular	MP:0005384	10.03	ADIPOQ DPP4 ENPP1 GCK IDE IGF1
9	cardiovascular system	MP:0005385	9.93	ADIPOQ DPP4 ENPP1 GCK IDE IGF1
10	digestive/alimentary	MP:0005381	9.92	GCG GHRL INS INSR LEP LEPR
11	immune system	MP:0005387	9.73	ADIPOQ DPP4 ENPP1 IDE IGF1 INS
12	integument	MP:0010771	9.28	ADIPOQ ENPP1 IDE IGF1 INS LEP

Sources

Drugs & Therapeutics for Glucose Intolerance

Drugs for Glucose Intolerance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 392)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Curcumin

Approved, Investigational

Phase 4

458-37-7, 84765-67-3

969516

Orlistat

Approved, Investigational

Phase 4

96829-58-2

3034010

Dexmedetomidine

Approved, Experimental, Vet_approved

Phase 4

86347-14-0, 113775-47-6

68602 5311068

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4

437-38-7

3345

Morphine

Approved, Investigational

Phase 4

57-27-2

5288826

Ethanol

Approved

Phase 4

64-17-5

702

Pitavastatin

Approved

Phase 4

147511-69-1

5282452

Rosiglitazone

Approved, Investigational

Phase 4

122320-73-4, 155141-29-0

77999

Losartan

Approved

Phase 4

114798-26-4

3961

Fluspirilene

Approved, Investigational

Phase 4

1841-19-6

3396

Lisinopril

Approved, Investigational

Phase 4

83915-83-7, 76547-98-3

5362119

Hydrochlorothiazide

Approved, Vet_approved

Phase 4

58-93-5

3639

Nebivolol

Approved, Investigational

Phase 4

152520-56-4, 99200-09-6, 118457-14-0

71301

Telmisartan

Approved, Investigational

Phase 4

144701-48-4

65999

Nitric Oxide

Approved

Phase 4

10102-43-9

145068

Nateglinide

Approved, Investigational

Phase 4

105816-04-4

60026

Hydroxychloroquine

Approved

Phase 4

118-42-3

3652

Glucagon

Approved

Phase 4

16941-32-5

16133228 16186314

Dulaglutide

Approved, Investigational

Phase 4

923950-08-7

Mecobalamin

Approved, Investigational

Phase 4

13422-55-4

Hydroxocobalamin

Approved

Phase 4

13422-51-0

15589840 44475014

Empagliflozin

Approved

Phase 4

864070-44-0

73151030 11949646

Methyltestosterone

Approved

Phase 4

58-18-4

6010

Testosterone undecanoate

Approved, Investigational

Phase 4

5949-44-0

21873174 65157

Testosterone enanthate

Approved

Phase 4

315-37-7

9416

Testosterone

Approved, Investigational

Phase 4

58-22-0

5408 6013

Valsartan

Approved, Investigational

Phase 4

137862-53-4

60846

Dapagliflozin

Approved

Phase 4

461432-26-8

9887712

Nutmeg

Approved

Phase 4

Metformin

Approved

Phase 4

1115-70-4, 657-24-9

4091

Bromocriptine

Approved, Investigational, Withdrawn

Phase 4

25614-03-3

31101

Atorvastatin

Approved

Phase 4

134523-00-5

60823

Acarbose

Approved, Investigational

Phase 4

56180-94-0

441184 444254

Angiotensin II

Approved, Investigational

Phase 4

68521-88-0, 11128-99-7, 4474-91-3

172198

Candesartan cilexetil

Approved

Phase 4

145040-37-5

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Dextroamphetamine

Approved, Illicit, Investigational

Phase 4

51-64-9, 300-62-9

5826 3007

Saxagliptin

Approved

Phase 4

361442-04-8

11243969

Amlodipine

Approved

Phase 4

88150-42-9

2162

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

23431961

Sildenafil

Approved, Investigational

Phase 4

139755-83-2, 171599-83-0

5212 135398744

Quinapril

Approved, Investigational

Phase 4

82586-55-8, 85441-61-8

54892

Cholecalciferol

Approved, Nutraceutical, Vet_approved

Phase 4

67-97-0, 1406-16-2

5280795 10883523

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 4

59-30-3

6037

Cyanocobalamin

Approved, Nutraceutical

Phase 4

68-19-9

24892734 16212801 44176380

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

2,4-thiazolidinedione

Investigational

Phase 4

2295-31-0

5437

Cobalamin

Experimental

Phase 4

13408-78-1

6857388

Candesartan

Experimental

Phase 4

139481-59-7

2541

Analgesics

Phase 4

Interventional clinical trials:

(show top 50) (show all 656)

#	Name	Status	NCT ID	Phase	Drugs
1	Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity	Unknown status	NCT01960205	Phase 4	Saxagliptin;saxagliptin;metformin
2	Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation	Unknown status	NCT00858676	Phase 4	acarbose
3	Effect of Oral Supplementation With Curcumin on Insulin Sensitivity in Subjects With Prediabetes	Unknown status	NCT03917784	Phase 4	Curcumin;Starch
4	Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance	Unknown status	NCT00733174	Phase 4	Rosiglitazone;Placebo
5	Research of Intensive Metabolic Intervention Before Pregnancy in Polycystic Ovary Syndrome	Unknown status	NCT03383068	Phase 4	Acarbose 100 MG;Exenatide;Orlistat;Metformin
6	Antiatherogenic and Antimetabolic Effect of Curcumin Therapy in the Prevention and Delay of Type 2 Diabetic in Patients With Impaired Glucose Tolerance and Insulin Resistance	Unknown status	NCT01052025	Phase 4	Curcumin
7	Intensity of Exercise and Glucose Metabolism	Unknown status	NCT01649219	Phase 4
8	The Effect of Sitagliptin Treatment on Glucose Metabolism and Endothelial Function in Renal Transplant Recipients - JANUVIA-08	Completed	NCT00740363	Phase 4	sitagliptin;placebo
9	Effect of Dexmedetomidine on Postoperative Glucose Levels and Insulin Secretion Patterns in Obese Patients With Impaired Glucose Tolerance.	Completed	NCT03809182	Phase 4	Dexmedetomidine;0.9% Sodium-chloride;Fentanyl;Morphine Sulfate
10	Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients	Completed	NCT02355509	Phase 4	Acarbose;Placebo
11	Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT)	Completed	NCT00301392	Phase 4	Life style interventions plus concomitant use of pitavastatin.
12	Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2 - EVIDENS	Completed	NCT01497132	Phase 4	Vitamin D3;Placebo
13	A Long-term, Multicentre, Double-blind, Randomised Parallel-group Trial to Determine Whether Reducing Post-prandial Glycaemia Can Reduce Cardiovascular-related Morbidity and Mortality in Patients With Established Coronary Heart Disease or Acute Coronary Syndrome Who Have Impaired Glucose Tolerance	Completed	NCT00829660	Phase 4	Acarbose;Matching Placebo
14	Effect of Dapagliflozin on Blood Pressure Variability in Patients With Prediabetes and Prehypertension Without Pharmacological Treatment	Completed	NCT03006471	Phase 4	Dapagliflozin;Placebo - Cap
15	Effects of Physical Exercise Versus Rosiglitazone on Endothelial Function in Coronary Artery Disease Patients With Prediabetes	Completed	NCT00675740	Phase 4	rosiglitazone
16	Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes	Completed	NCT02700334	Phase 4	Dapagliflozin;Placebo
17	Effect of Linagliptin + Metformin vs Metformin Alone on the Role of Pancreatic Islet Function, Insulin Resistance and Markers of Cardiovascular Risk in Patients With Prediabetes: Randomized Clinical Trial	Completed	NCT03004612	Phase 4	Metformin
18	Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes; A Proof-of-concept, Randomized, Double-blind, Parallel-group Placebo-controlled Study	Completed	NCT01964703	Phase 4	Rubus occidentalis extract
19	Effect of Linagliptin + Metformin on Glucose Metabolism and Pancreatic Beta Cell Function in Patients With Prediabetes Who do Not Achieve Normoglycemia After 12 Months of Treatment With Metformin Alone	Completed	NCT04088461	Phase 4	Linagliptin / Metformin Oral Tablet;Metformin
20	Postmarketing Clinical Study on AO-128	Completed	NCT02287402	Phase 4	AO-128
21	Coronary Artery Disease Progression by iMap Intravascular Ultrasound Analysis in Patients With Prediabetes	Completed	NCT02744976	Phase 4	Metformin
22	The Effect of Exenatide on Body Weight, Energy Expenditure and Hunger in Obese Women Without Diabetes Mellitus	Completed	NCT00456885	Phase 4	exenatide;Placebo
23	Blood Pressure and Metabolic Effects of Nebivolol Compared With Hydrochlorothiazide and Placebo in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose	Completed	NCT00673790	Phase 4	Nebivolol with concomitant losartan or lisinopril;HCTZ with concomitant losartan or lisinopril;Placebo with concomitant losartan or lisinopril
24	Effect of Pioglitazone With and Without Exenatide on Body Weight, Fat Topography, Beta Cell Function, and Glycemic Control in Type 2 Diabetic Patients	Completed	NCT00845182	Phase 4	Pioglitazone;Exenatide;Pioglitazone and Exenatide
25	The Chronic and Acute Postprandial Vascular Effects of Exenatide vs. Metformin in Abdominally Obese Patients With Impaired Glucose Tolerance	Completed	NCT00546728	Phase 4	Exenatide;Metformin
26	Comparative Effects of Antidiabetic Medications on Postprandial Hyperlipidemia, Free Fatty Acid Signaling, and Endothelial Dysfunction in Individuals With Prediabetes	Completed	NCT02104739	Phase 4	Exenatide;Saxagliptin;Exenatide extended-release (ER)
27	Telmisartan vs. Losartan in Hypertensive Patients With Impaired Glucose Tolerance: A Comparison of Their Antihypertensive, Metabolic, and Vascular Effects	Completed	NCT00407862	Phase 4	Telmisartan 80 mg;Losartan 50 mg
28	Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance	Completed	NCT00108615	Phase 4	Metformin;Pioglitazone
29	Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance IGT and Type 2 Diabetes T2D in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome PCOS	Completed	NCT03122041	Phase 4	Sitagliptin
30	Effects of GH and Pioglitazone in Viscerally Obese Adults With IGT	Completed	NCT00352287	Phase 4	Recombinant human growth hormone; pioglitazone
31	Efficacy and Safety of Nateglinide Treatment in Renal Treatment Recipients With Post Transplant Diabetes Mellitus or Impaired Glucose Tolerance	Completed	NCT00319189	Phase 4	Nateglinide
32	A Single Center, Open Label, Single Arm Trial To Evaluate The Effect Of Twenty Four Weeks Of Treatment With 80 Mg To 320 Mg Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance (Igt)	Completed	NCT00241072	Phase 4	valsartan
33	Diet and Exercise in Type 2 Diabetes and Prediabetes	Completed	NCT00928005	Phase 4
34	The Assessment of the Effect of Metformin and Its Serum Concentration on the Concentration of Substances Associated With the Production of Nitric Oxide in Patients With Impaired Carbohydrate Metabolism	Completed	NCT03398356	Phase 4	Metformin
35	Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation	Completed	NCT00974272	Phase 4	Exenatide
36	Phase IV Study Evaluating the Effect of Sitagliptin (Januvia™) on Beta-cell Function in Patients With Acute Myocardial Infarction or Unstable Angina Pectoris and Newly Detected Impaired Glucose Tolerance or Type 2 Diabetes.	Completed	NCT00627744	Phase 4	Sitagliptin
37	Exercise in Elderly Individuals With Impaired Glucose Tolerance: Beneficial for Vasculature and Neurons?	Completed	NCT01219231	Phase 4
38	The Effect of Metformin on Clinical Course of Ischemic Etiology Chronic Heart Failure in Patients With Prediabetes: the Open-label Randomized Clinical Trial	Completed	NCT04549415	Phase 4	Metformin Hydrochloride
39	Oral Cholecalciferol in Prevention of Type 2 DM in Prediabetic Population With Vitamin D Insufficiency	Completed	NCT01436916	Phase 4	oral cholecalciferol + life style counselling;placebo + life style counselling
40	Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes	Completed	NCT01326533	Phase 4	hydroxychloroquine
41	Effects of Metformin on Longevity Gene Expression and Inflammation and Prediabetic Individuals. A Placebo-controlled Trial	Completed	NCT01765946	Phase 4	Metformin;placebo
42	Effect of Exenatide on Brain Glucose Uptake in Relations to Pancreatic, Adipose Tissue, and Hepatic Function	Completed	NCT01588418	Phase 4	Exenatide;Placebo
43	The Effect of Korean Red Ginseng Supplementation on Glucose Control in Subjects With Impaired Fasting Glucose, Impaired Glucose Tolerance or Newly-diagnosed Type 2 Diabetes Mellitus	Completed	NCT01911663	Phase 4
44	GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response	Recruiting	NCT04387201	Phase 4	Cyanocobalamin;Dulaglutide
45	52 Week RCT to Investigate the Effect of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Obese/Overweight Men With T2DM/Prediabetes and Hypogonadism and Subsequent 108 Week Open Label Phase to Investigate Effects on Cardiometabolic Parameters	Recruiting	NCT03851627	Phase 4	Testosterone Undecanoate;Placebo
46	The Role of the Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose Metabolism Among African Americans: Pilot Study	Recruiting	NCT03938389	Phase 4	Sacubitril-Valsartan Tab 97-103 MG;Valsartan 160mg;Placebo Oral Tablet
47	Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes	Recruiting	NCT05119179	Phase 4	Semaglutide
48	Use of Empagliflozin to Treat Prediabetes - a Randomized, Double-blind, Placebo-controlled 13-week Intervention Trial	Recruiting	NCT05426525	Phase 4	Empagliflozin;Multivitamin-Placebo
49	Effect of Administration of Berberine Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Patients With Prediabetes	Active, not recruiting	NCT03029390	Phase 4	Metformin
50	The Effect of Dapagliflozin on the Short-term Prognosis of Patients With Acute Myocardial Infarction	Not yet recruiting	NCT05050500	Phase 4	Dapagliflozin 10mg/Tab;Placebo

Search NIH Clinical Center for Glucose Intolerance

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

glucomannan

Cochrane evidence based reviews: glucose intolerance

Sources

Genetic Tests for Glucose Intolerance

Genetic tests related to Glucose Intolerance:

#	Genetic test	Affiliating Genes
1	Glucose Intolerance ²⁸

Sources

Anatomical Context for Glucose Intolerance

Organs/tissues related to Glucose Intolerance:

MalaCards : Pancreatic Islet, Skeletal Muscle, Ovary, Liver, Heart, Adipocyte, Endothelial

Sources

Publications for Glucose Intolerance

Articles related to Glucose Intolerance:

(show top 50) (show all 11339)

#	Title	Authors	PMID	Year
1	Serum 25-hydroxy vitamin d and insulin resistance, metabolic syndrome, and glucose intolerance among Arab Americans. ⁵³ ⁶²	Pinelli NR...Herman WH	20332348	2010
2	Structure guided design of 5-arylindazole glucocorticoid receptor agonists and antagonists. ⁵³ ⁶²	Yates CM...Trump RP	20469868	2010
3	Adiponectin is independently associated with apolipoprotein B to A-1 ratio in Koreans. ⁵³ ⁶²	Park JS...Lee HC	19914667	2010
4	Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. ⁵³ ⁶²	Garcia-Tornadu I...Becu-Villalobos D	20147524	2010
5	Obesity and type 2 diabetes: slow down!--Can metabolic deceleration protect the islet beta cell from excess nutrient-induced damage? ⁵³ ⁶²	Andrikopoulos S	19815054	2010
6	Adiponectin and carotid intimal medial thickness in subjects with and without glucose intolerance (CURES-82). ⁵³ ⁶²	Gokulakrishnan K...Mohan V	20105040	2010
7	Leptin and the metabolic syndrome in patients with myotonic dystrophy type 1. ⁵³ ⁶²	Rakocevic Stojanovic V...Apostolski S	19804472	2010
8	Retinol-binding protein 4 levels in obese children and adolescents with glucose intolerance. ⁵³ ⁶²	Yeste D...Carrascosa A	20389103	2010
9	Adiponectin in insulin resistance: lessons from translational research. ⁵³ ⁶²	Ziemke F...Mantzoros CS	19906806	2010
10	Human serum metabonomic analysis reveals progression axes for glucose intolerance and insulin resistance statuses. ⁵³ ⁶²	Zhang X...Ji L	19697961	2009
11	Acromegaly pathogenesis and treatment. ⁵³ ⁶²	Melmed S	19884662	2009
12	The prevalence and risk factors for glucose intolerance in young Korean women with polycystic ovary syndrome. ⁵³ ⁶²	Lee H...Cho WY	19688613	2009
13	The prevalence of abnormal liver enzymes and metabolic syndrome in obese adolescent females with polycystic ovary syndrome. ⁵³ ⁶²	Barfield E...Shah B	19576817	2009
14	Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose. ⁵³ ⁶²	Hofso D...Hjelmesaeth J	19542241	2009
15	Cassia cinnamon for the attenuation of glucose intolerance and insulin resistance resulting from sleep loss. ⁵³ ⁶²	Jitomir J...Willoughby DS	19627193	2009
16	Pre-gravid physical activity and reduced risk of glucose intolerance in pregnancy: the role of insulin sensitivity. ⁵³ ⁶²	Retnakaran R...Hanley AJ	18793347	2009
17	Impact of adiponectin and ghrelin on incident glucose intolerance and on weight change. ⁵³ ⁶²	Bennett NR...Forrester TE	18624998	2009
18	Visceral obesity is associated with the metabolic syndrome and elevated plasma retinol binding protein-4 level in obstructive sleep apnea syndrome. ⁵³ ⁶²	Makino S...Sugimoto T	19003725	2009
19	Early atherosclerosis and vascular inflammation in mice with diet-induced type 2 diabetes. ⁵³ ⁶²	Bartels ED...Nielsen LB	19260948	2009
20	Association between insulin resistance, glucose intolerance, and hypertension in pregnancy. ⁵³ ⁶²	Negrato CA...Rudge MV	18847384	2009
21	A cross-sectional study for glucose intolerance of myotonic dystrophy. ⁵³ ⁶²	Matsumura T...Shinno S	18834994	2009
22	Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. ⁵³ ⁶²	Rossi B...Hoeger KM	18812482	2008
23	[Polymorphism of glucose intolerance and insulin resistance susceptibility genes in oncological patients]. ⁵³ ⁶²	Ulybina IuM...Bershtein LM	19140314	2008
24	Ketogenic diet-fed rats have increased fat mass and phosphoenolpyruvate carboxykinase activity. ⁵³ ⁶²	Ribeiro LC...Gottfried C	18655006	2008
25	Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome. ⁵³ ⁶²	Tasali E...Ehrmann DA	18647805	2008
26	Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. ⁵³ ⁶²	Tomlinson JW...Stewart PM	18633104	2008
27	Associations between sex hormone binding globulin and metabolic syndrome parameters in premenopausal obese women. ⁵³ ⁶²	Akin F...Kaptanoglu B	19008614	2008
28	Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. ⁵³ ⁶²	Zhang X...Cai D	18854155	2008
29	Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. ⁵³ ⁶²	Makita S...Nakamura M	18803955	2008
30	High plasma retinol binding protein-4 and low plasma adiponectin concentrations are associated with severity of glucose intolerance in women with previous gestational diabetes mellitus. ⁵³ ⁶²	Choi SH...Jang HC	18492757	2008
31	A cross-sectional study of the association between persistent organic pollutants and glucose intolerance among Greenland Inuit. ⁵³ ⁶²	Jorgensen ME...Bjerregaard P	18560802	2008
32	Effect of low-dose oral contraceptives on metabolic risk factors in African-American women. ⁵³ ⁶²	Frempong BA...Sumner AE	18334585	2008
33	Chromium alleviates glucose intolerance, insulin resistance, and hepatic ER stress in obese mice. ⁵³ ⁶²	Sreejayan N...Ren J	18388893	2008
34	Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. ⁵³ ⁶²	Aroda V...Henry RR	17706206	2008
35	Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. ⁵³ ⁶²	Rajpathak SN...Kaplan RC	17904401	2008
36	Adiponectin and its role in cardiovascular diseases. ⁵³ ⁶²	Beltowski J...Widomska S	18336252	2008
37	Insulin and its role in chronic kidney disease. ⁵³ ⁶²	Mak RH	17929061	2008
38	Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance. ⁵³ ⁶²	Itou M...Sata M	17944883	2008
39	Suppressive effects of diacylglycerol oil on postprandial hyperlipidemia in insulin resistance and glucose intolerance. ⁵³ ⁶²	Ai M...Shimokado K	17125771	2007
40	How many components for the metabolic syndrome? Results of exploratory factor analysis in the FIBAR study. ⁵³ ⁶²	Mannucci E...Rotella CM	17387006	2007
41	Glucocorticoids and cardiovascular disease. ⁵³ ⁶²	Walker BR	17984234	2007
42	Muscle GLUT4 in cirrhosis. ⁵³ ⁶²	Holland-Fischer P...Vilstrup H	17448565	2007
43	Fetal determinants of type 2 diabetes. ⁵³ ⁶²	Reusens B...Remacle C	17691930	2007
44	Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. ⁵³ ⁶²	Lubos E...Blankenberg S	16814296	2007
45	Early-phase insulin secretion is disturbed in obese subjects with glucose intolerance. ⁵³ ⁶²	Mizuno A...Doi T	17512320	2007
46	Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis. ⁵³ ⁶²	Hammana I...Rabasa-Lhoret R	17418606	2007
47	[Effect of progressive insulin resistance on the correlation of glucose metabolism and bone status]. ⁵³ ⁶²	Buday B...Koranyi L	17561482	2007
48	Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. ⁵³ ⁶²	Hitti J...AIDS Clinical Trials Group 5084 Study Team	17403409	2007
49	Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. ⁵³ ⁶²	Florescu D...Kotler DP	17503657	2007
50	'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic Studies. ⁵³ ⁶²	Gurnell M	17389771	2007

Sources

Genes for Glucose Intolerance

Genes related to Glucose Intolerance (1 elite genes):

(show top 50) (show all 59)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MT-TL1	Mitochondrially Encoded TRNA-Leu (UUA/G) 1	RNA Gene	400	Pathogenic ⁵
2	INS	Insulin	Protein Coding	30.63	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8593759 12853008 16129731 (more) 8622611 17503657 9321743 20147524 15319810 15353412 19697961 9794098 18847384 8012426 1446794 8542740 9314636 11231980 16618974 18647805 15615809 8200997 1315588 19914667 19688613 18560802 8557064 17125771 18334585 16448988 17403409 1678646 19627193 16026378 8027259 2229300 1904090 7587007 8822314 9313755 15254872 11679468 11423512 10459563 9431856 8206582 1959706 19140314 18388893 18370717 15220191 15105990 8840171 1769438 20332348 19087394 19003725 17929061 8010722 1877473 1860554 2210122 2115296 17691930 17473485 15254589 9550122 9328546 9267146 8969930 8946270 15637182 11812745 9544854 9536214 9283783 7806019 2404717 16801590 8041868 8306480 1468279 17512320 15679072 12870237 12687350 12590018 11833046 10203292 9925352 8846683 7869936 18793347 15563978 16380496 11855690 11011219 10462370 10444812 10657739
3	ADIPOQ	Adiponectin, C1Q And Collagen Domain Containing	Protein Coding	26.46	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16546285 20105040 15792679 (more) 16259488 19914667 17418606 14602778 17561482 18492757 19906806 18803955 19542241 16595853 15049945 17706206 15902402 18834994 18624998 18336252 16381996
4	LEP	Leptin	Protein Coding	25.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12654711 15754841 16129731 (more) 10490782 15312578 18854155 16282336 19804472 11230277 15815193 16236542
5	GCG	Glucagon	Protein Coding	24.06	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17944883 8435987 10024091 (more) 16049395 11237222
6	RETN	Resistin	Protein Coding	23.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11809189 16814296 16669997 (more) 15254589
7	SLC2A4	Solute Carrier Family 2 Member 4	Protein Coding	23.06	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9950801 15063922 16187315 (more) 17448565
8	INSR	Insulin Receptor	Protein Coding	23.04	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7983789 8822314 9702422 (more) 10867718 9104736 15118262 15677494 1547686 11928588 8225693
9	GCK	Glucokinase	Protein Coding	23.03	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9325299 8454109 8376578 (more) 9468341
10	IGF1	Insulin Like Growth Factor 1	Protein Coding	22.61	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17904401 1311795 7476303 (more) 17484056 1915083 15248820 15305891 15638297 19884662 11600528 16172212 8444124 11586502
11	SHBG	Sex Hormone Binding Globulin	Protein Coding	20.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19008614
12	LEPR	Leptin Receptor	Protein Coding	20.17	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10490782
13	GHRL	Ghrelin And Obestatin Prepropeptide	Protein Coding	19.55	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18624998
14	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	19.46	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17387006 19576817
15	IDE	Insulin Degrading Enzyme	Protein Coding	19.37	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12634421 17051221 15850385 (more) 16574064
16	PCK2	Phosphoenolpyruvate Carboxykinase 2, Mitochondrial	Protein Coding	19.1	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18655006
17	LPL	Lipoprotein Lipase	Protein Coding	18.55	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1542265
18	DPP4	Dipeptidyl Peptidase 4	Protein Coding	18.36	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17944883
19	ADRB3	Adrenoceptor Beta 3	Protein Coding	18.31	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9313101 9694585
20	ENPP1	Ectonucleotide Pyrophosphatase/Phosphodiesterase 1	Protein Coding	18.1	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16025115 16278247
21	IGFBP1	Insulin Like Growth Factor Binding Protein 1	Protein Coding	17.99	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17904401 10868969 9284705 (more) 11147791
22	GH1	Growth Hormone 1	Protein Coding	17.36	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11600528 19884662
23	RBP4	Retinol Binding Protein 4	Protein Coding	17.24	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19003725 20389103 18492757 (more) 16034410
24	IRS1	Insulin Receptor Substrate 1	Protein Coding	16.84	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
25	GYS1	Glycogen Synthase 1	Protein Coding	16.71	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8786726
26	IL6	Interleukin 6	Protein Coding	16.32	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
27	LMNA	Lamin A/C	Protein Coding	16.13	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders (show sections)	11243729 11440372 12145775
28	TNF	Tumor Necrosis Factor	Protein Coding	16.05	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
29	CRP	C-Reactive Protein	Protein Coding	15.78	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
30	UCP1	Uncoupling Protein 1	Protein Coding	15.64	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
31	PAX6	Paired Box 6	Protein Coding	15.36	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11756345 15842522
32	FOXO1	Forkhead Box O1	Protein Coding	15.31	DISEASES inferred ¹⁴ GeneCards inferred via : Functions (show sections)
33	CCL2	C-C Motif Chemokine Ligand 2	Protein Coding	15.16	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
34	ALB	Albumin	Protein Coding	15.04	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
35	TCF7L2	Transcription Factor 7 Like 2	Protein Coding	15.01	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
36	KCNJ11	Potassium Inwardly Rectifying Channel Subfamily J Member 11	Protein Coding	14.96	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
37	POMC	Proopiomelanocortin	Protein Coding	14.91	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
38	UCP2	Uncoupling Protein 2	Protein Coding	14.84	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
39	ACE	Angiotensin I Converting Enzyme	Protein Coding	14.82	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
40	ABCC8	ATP Binding Cassette Subfamily C Member 8	Protein Coding	14.73	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
41	FABP4	Fatty Acid Binding Protein 4	Protein Coding	14.6	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
42	SST	Somatostatin	Protein Coding	14.49	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
43	SERPINA6	Serpin Family A Member 6	Protein Coding	14.37	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10487686
44	GLP1R	Glucagon Like Peptide 1 Receptor	Protein Coding	14.33	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
45	NEUROG3	Neurogenin 3	Protein Coding	14.29	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
46	NOS3	Nitric Oxide Synthase 3	Protein Coding	14.29	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
47	APOA1	Apolipoprotein A1	Protein Coding	14.26	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
48	NEUROD1	Neuronal Differentiation 1	Protein Coding	14.19	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
49	FASN	Fatty Acid Synthase	Protein Coding	14.19	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
50	PRDM16	PR/SET Domain 16	Protein Coding	14.12	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Glucose Intolerance

ClinVar genetic disease variations for Glucose Intolerance:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	MT-TL1	NC_012920.1:m.3243A>G	SNV	Pathogenic	9589	rs199474657	GRCh37: MT:3243-3243 GRCh38: MT:3243-3243

Sources

Expression for Glucose Intolerance

Search GEO for disease gene expression data for Glucose Intolerance.

Sources

Pathways for Glucose Intolerance

Pathways directly related to Glucose Intolerance:

#	Pathway	Source
1	Defective SLC5A1 causes congenital glucose/galactose malabsorption (GGM)	Reactome ⁶⁶

Pathways related to Glucose Intolerance according to GeneCards Suite gene sharing:

(show all 27)

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.67	LEPR LEP INSR INS IGF1 IDE
2	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.83	SLC2A4 PCK2 INSR INS IGF1
3	IL-9 Signaling Pathways ⁶⁵ Show member pathways Adipocytokines and Insulin Signaling ⁶⁵ Common Cytokine Receptor Gamma-Chain Family Signaling Pathways ⁶⁵ Development Thrombopoietin-regulated cell processes ²² IL-15 Signaling Pathways ⁶⁵ IL-2 Signaling Pathways ⁶⁵ IL-21 Signaling Pathways ⁶⁵ IL-4 Pathway ⁶⁴ IL-4 Signaling Pathways ⁶⁵ IL-7 Signaling Pathways ⁶⁵ IL-9 Pathway ⁶⁴ Immune response IL-9 signaling pathway ²² Interleukin-9 signaling ⁶⁶	12.77	SLC2A4 RETN LEP INSR INS ADIPOQ
4	PPARA activates gene expression ⁶⁶ Show member pathways Regulation of lipid metabolism by PPARalpha ⁶⁶ Transcriptional regulation of white adipocyte differentiation ⁶⁶	12.43	SLC2A4 LPL LEP ADIPOQ
5	Angiopoietin-like protein 8 regulatory pathway ⁷⁴ Show member pathways Insulin signaling ⁷⁴ Liver X receptor pathway ⁷⁴	12.4	SLC2A4 LPL INSR ENPP1
6	Glucose / Energy Metabolism ³	12.4	SLC2A4 PCK2 INSR INS GCG ENPP1
7	Peptide hormone metabolism ⁶⁶ Show member pathways Glycoprotein hormones ⁶⁶ Metabolism of Angiotensinogen to Angiotensins ⁶⁶ Metabolism of Angiotensinogen to Angiotensins ⁷⁴ Peptide hormone biosynthesis ⁶⁶ Synthesis, secretion, and deacylation of Ghrelin ⁶⁶ thyroid hormone biosynthesis ⁶¹	12.14	LEP INS IGF1 GHRL GCG DPP4
8	AMPK Enzyme Complex Pathway ⁶⁴ Show member pathways Chromatin Remodeling ⁶⁴	12.1	SLC2A4 LEP INSR INS
9	AMP-activated protein kinase signaling ⁷⁴ Show member pathways AMPK Signaling Pathway ⁶⁷ Leptin and adiponectin ⁷⁴	11.96	ADIPOQ INS INSR LEP LEPR SLC2A4
10	PPAR signaling pathway ⁷⁴ Show member pathways FABP4 in ovarian cancer ⁷⁴ Fatty acid transporters ⁷⁴	11.73	PCK2 LPL ADIPOQ
11	Mesenchymal Stem Cells and Lineage-specific Markers ⁶⁵	11.61	SLC2A4 LPL LEP INS IGF1 ADIPOQ
12	Incretin synthesis, secretion, and inactivation ⁶⁶ Show member pathways Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) ⁶⁶ Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) ⁶⁶	11.54	DPP4 GCG LEP
13	Development_Leptin signaling via PI3K-dependent pathway ²²	11.48	SLC2A4 LEPR LEP
14	Signaling events mediated by PTP1B ⁶¹	11.44	LEPR LEP INSR INS
15	FOXA2 and FOXA3 transcription factor networks ⁶¹ Show member pathways FOXA transcription factor networks ⁶¹	11.38	LPL INS GCK
16	Adipogenesis ⁷⁴	11.34	SLC2A4 RETN PCK2 LPL LEP INS
17	Nonalcoholic fatty liver disease ⁷⁴	11.32	LEPR LEP INSR INS ADIPOQ
18	Leptin-insulin signaling overlap ⁷⁴ Show member pathways Signaling by Leptin ⁶⁶	11.2	LEPR LEP INSR INS
19	Anti-diabetic Drug Potassium Channel Inhibitors Pathway, Pharmacodynamics ⁶⁰	11.17	INSR INS GCK
20	Type II diabetes mellitus ⁷⁴	11.05	SLC2A4 INSR ADIPOQ
21	Roles of ceramides in the development of insulin resistance ⁷⁴	11.04	SLC2A4 INSR INS
22	Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics ⁶⁰	11.01	LEPR LEP INS GHRL
23	Insulin-mediated glucose transport ⁶¹	10.97	INS INSR SLC2A4
24	Cori cycle ⁷⁴	10.9	SLC2A4 INS GPT
25	Insulin signaling in adipocytes (diabetic condition) ⁷⁴ Show member pathways IL-4 signaling pathway ⁷⁴ Insulin signaling in adipocytes (normal condition) ⁷⁴	10.86	SLC2A4 INSR
26	Transcription factor regulation in adipogenesis ⁷⁴	10.7	SLC2A4 PCK2 LEP INSR ADIPOQ
27	SCFA and skeletal muscle substrate metabolism ⁷⁴	10.37	SLC2A4 GCG

Sources

GO Terms for Glucose Intolerance

Cellular components related to Glucose Intolerance according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.98	RETN LPL LEP INS IGF1 IDE
2	extracellular region	GO:0005576	9.7	ADIPOQ DPP4 ENPP1 GCG GHRL IDE

Biological processes related to Glucose Intolerance according to GeneCards Suite gene sharing:

(show all 29)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of protein kinase B signaling	GO:0051897	10.18	LEP INSR INS IGF1
2	positive regulation of MAPK cascade	GO:0043410	10.15	ADRB3 GHRL IGF1 INS INSR LEP
3	positive regulation of cold-induced thermogenesis	GO:0120162	10.13	LEPR LEP GHRL ADRB3 ADIPOQ
4	carbohydrate metabolic process	GO:0005975	10.11	SLC2A4 INSR INS GCK ADRB3
5	generation of precursor metabolites and energy	GO:0006091	10.1	ADIPOQ ADRB3 ENPP1
6	positive regulation of insulin secretion	GO:0032024	10.1	GCK GHRL PCK2
7	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	10.1	IGF1 INS INSR LEP
8	regulation of insulin secretion	GO:0050796	10.09	GCG GCK LEP
9	response to activity	GO:0014823	10.09	LEP GCG ADIPOQ
10	gluconeogenesis	GO:0006094	10.08	PCK2 LEPR GCG
11	brown fat cell differentiation	GO:0050873	10.02	ADIPOQ ADRB3 SLC2A4
12	glucose metabolic process	GO:0006006	10.02	LEP INS GHRL GCK ADIPOQ
13	positive regulation of mitotic nuclear division	GO:0045840	10.01	INSR INS IGF1
14	positive regulation of glucose import	GO:0046326	10.01	INSR INS IGF1 ADIPOQ
15	activation of protein kinase B activity	GO:0032148	10	INSR INS IGF1
16	positive regulation of glycolytic process	GO:0045821	9.95	INSR INS IGF1
17	cellular response to leptin stimulus	GO:0044320	9.94	GCK LEP
18	positive regulation of respiratory burst	GO:0060267	9.93	INSR INS
19	energy reserve metabolic process	GO:0006112	9.93	ADRB3 LEP LEPR
20	bone mineralization involved in bone maturation	GO:0035630	9.9	LEP IGF1
21	regulation of bone remodeling	GO:0046850	9.89	LEPR LEP
22	bone growth	GO:0098868	9.88	LEPR LEP
23	negative regulation of feeding behavior	GO:2000252	9.87	RETN INS
24	positive regulation of developmental growth	GO:0048639	9.86	INSR LEP
25	negative regulation of gluconeogenesis	GO:0045721	9.86	ADIPOQ GCK INS LEPR
26	glucose homeostasis	GO:0042593	9.86	ADIPOQ GCG GCK INS INSR LEP
27	response to nutrient levels	GO:0031667	9.82	LEP GHRL ADIPOQ
28	positive regulation of glycogen biosynthetic process	GO:0045725	9.76	INSR INS IGF1 GCK
29	cellular response to insulin stimulus	GO:0032869	9.53	SLC2A4 PCK2 LEP INSR GPT GCK

Molecular functions related to Glucose Intolerance according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	insulin receptor binding	GO:0005158	9.63	INS IGF1 ENPP1
2	insulin binding	GO:0043559	9.56	INSR IDE
3	hormone activity	GO:0005179	9.44	RETN LEP INS IGF1 GHRL GCG
4	insulin-like growth factor receptor binding	GO:0005159	9.43	INSR INS IGF1